drugset
drugset / Trial / NCT04708236

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

NCT04708236 ↗

Phase 1/2 Withdrawn Oryn Therapeutics, LLC
RandomizedSequentialQuadruple-blindTreatment

Summary

Evaluate the safety and effect of ORTD-1 on COVID-19 related pneumonia.

Timeline

Start
2021-04
Primary completion
2021-05
Completion
2021-07

Outcome

Outcome not reported

Stopped (Enrollment): “recruitment”

Drugs

EvaluationDrugModalityDoseRoute
Subject ORTD-1 Unknown — Intravenous

Indications

COVID-19